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Cover Letter 
 
Dear Professor Zuberi, 
 
Many thanks for your consideration of our manuscript. We have addressed 
the UHYLHZHUV¶ comments in detail below. Changes to the manuscript have 
been highlighted in green. We hope that our revisions meet with your 
approval.  
 
Comments from the editors and reviewers: 
-Reviewer 1 
 
-  
Yates et al. present a series of five female patients with pathogenic variants in 
the SLC35A2 gene which is associated with Congenital Disorders of 
Glycosylation (CDG) type IIm. They have also sought to review the existing 
literature in order to define the phenotype of this condition more clearly. 
The data they provide in support of the pathogenicity of these variants is 
strong, particularly since all have arise de novo. They have also gathered a 
reasonable amount of clinical detail in each case. The novel aspects that this 
paper provides on SLC35A2 are that they report cerebral visual impairment as 
a phenotypic feature, and they report Tetralogy of Fallot in one case. 
I feel that there has been a slight missed opportunity here to provide the 
reader with a better grasp of this rare condition. Too much manuscript space 
has been devoted to the narrative of the case histories (details of which are 
completely replicated in table 1) whilst the phenotypic detail provided on the 
14 published cases is a little weak (for example, we are only told if they have 
seizures or not, not what type of seizure nor the age of presentation).  
Thank you for this comment. The table describing all published cases has 
been updated with age of seizure onset and types of seizures.  
Further detail has been added in the discussion in respect to the seizure 
phenotype and MRI brain findings, including previously published cases.  
 
 
An overall analysis of the phenotypic spectrum (taking new and published 
cases into account) is lacking. 
Many thanks. A section has been added to the discussion to summarise the 
cardinal features of the published cases.  
 
Given the lack of precision of detail on medication response I do not think the 
title ³WUHDWPHQW VWUDWHJLHV´ is appropriate.  
Thank you. The title has now been altered.  
 
The methods section of this manuscript is unsuitably short and vague. 
Many thanks ± the methods section has been updated with additional detail 
regarding sequencing methodology. The methods are described in further 
detail in the supplementary material.  
 
Re; Title: 
3 
 
Can you call this ³SLC35A2-related epileptic encephalopathy: patient VHULHV´ 
when one of the cases you report did not have epilepsy? Can you call this 
³WUHDWPHQW VWUDWHJLHV´ when you provide no substantive evidence to support 
any given treatment approach. 
Many thanks for this. The title has been altered.  
 
 
Re: Methods: 
Reading through the supplementary material and looking at the affiliations of 
the authors it is apparent that these patients have been recruited and had 
genetic testing in a variety of centres. It is not clear in the methods therefore 
how this cohort has been put together. It would be helpful if the authors could 
explain this in more detail in the methods ± for example was a gene matching 
website used?  
Thank you. Details have been added to the methods section regarding the 
cohort and how it was formed.  
 
Also it should be explained on what basis patients at each centre were 
selected for genetic testing since this will affect the ascertainment of the 
cases and the phenotype described. For example if one centre was only doing 
WES on patients with infantile spasms this would result in a potential bias 
which ought to be disclosed. 
NEED TO DOUBLE CHECK WITH AUTHORS 
 
Re: Results: 
Most of the details within the patient reports section of the results are 
duplicated in table 1. The patient reports are largely in keeping with the 
previously published cases (apart from the new features of visual impairment 
and Tetralogy of Fallot) so this section does not provide any novel insights. I 
think the manuscript would be stronger if the results section took a more 
analytical approach to the epilepsy phenotypes of the new and published 
cases. If they did this then a better title would perhaps be ³SLC35A2: Defining 
the epilepsy SKHQRW\SH´ (see Title comment above) 
Thank you. The results section now includes a more in-depth analysis of the 
epilepsy phenotype.  
 
The precision of detail on medication response is inadequate. What does 
³SDUWLDO UHVSRQVH´ (case 1, case 2) mean and ZKR¶V assessment was this? A 
more structures approach to assessment and reporting of medication 
response is needed.  
Thank you - we define partial response as a decrease in seizure frequency 
and/or duration without complete control of epilepsy. This was assessed by 
the individual clinicians looking after each patient, which was a Clinical 
Geneticist and Paediatric Neurologist in most cases.  
 
Minor: 
Consistency with hyphenation see ³WR-GDWH´ or ³WR GDWH´ 
Thank you, this has been updated.  
 
With X-inactivation say which allele the skewing is in favour of 
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Thank you ± the skewing is 100% therefore this is in favour of the pathogenic 
allele.  
 
Consider use of most up to date ILAE terminology. See Scheffer 2017, 
Epilepsia 
- - ³'HYHORSPHQWDO and epileptic HQFHSKDORSDWK\´ not ³HSLOHSWLF 
HQFHSKDORSDWK\´ 
- - ³'UXJ-resistant HSLOHSV\´ not ³UHIUDFWRU\´ 
Thank you, this has been altered accordingly.  
 
Do these patients truly have West syndrome? Or do you think that the 
definition of West syndrome depends on developmental plateau or 
regression?  
Thank you ± in the manuscript, we have defined West syndrome as the triad 
of infantile spasms, hypsarrhythmia and developmental delay rather than 
plateau/regression.  
 
It would be good to have data on any developmental assessments prior to 
presentation with epileptic spasms. 
Thank you for this comment. Unfortunately, as most patients present with 
early-onset seizures, we would have to assume that developmental delay 
presented before epilepsy.  
 
It is difficult to make any comment on treatment response in this specific 
group of patients. The treatments reported as successful here are the ones 
that most typically used to treat infantile spasms. The authors should 
acknowledge this as a limitation. 
Thank you, the treatment section in the discussion has been altered to reflect 
the standard treatments being used and lack of specific therapies in this group 
of patients.  
 
Discussion would benefit from a broader discussion of the relationship 
between CDGs and severe early onset epilepsy. It would seem that this CDG 
is quite unique in that nearly all known cases have a severe early onset 
epilepsy. I think this is worth mentioning. 
Thank you, a mention of this has been added to the discussion.  
 
At the bottom of paragraph 2 page 12 there is a line ³,Q the literature, these 
have been reported at approximately equal IUHTXHQF\´ I think this is with 
reference to missense and nonsense variants being observed with equal 
frequency, but this is not clear. There are also frameshift variants observed in 
the literature which you have not mentioned. 
Thank you. This has been revised to state that missense and truncating 
variants have been reported with equal frequency. 
 
Would you recommend transferrin isoelectric focussing as a diagnostic test 
when a female presents with infantile spasms? This series would suggest that 
this does not usually happen. 
Thank you, a sentence has been added to recommend this as a diagnostic 
test, emphasising the need to perform this before three years of age.  
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Tables: 
If you want to include reference to treatment response in the paper please 
include AEDs used and what treatment response was seen (as precisely as 
possible) in table 1.  
Thank you, however, we do not have enough data to make firm conclusions 
on this.  
 
Please include details of MRI abnormalities in table 1 
Many thanks, these details have been added to the table.  
 
Please include head circumference measurements and centiles in table 1, if 
available. 
Thank you, the centiles for head circumference have been added.  
 
Please include severity of cognitive impairment and details of seizure type (at 
presentation and evolution) in table 2.  
 
Thank you, the severity of developmental delay/intellectual disability has been 
included in table 2. Further details of seizures have also been added.  
 
In table 2 please spell de novo fully rather than putting ³GQ´ 
Thank you, this has been altered.  
 
-Reviewer 2 
 
-  
Yates and colleagues describe in detail the clinical phenotypes and treatment 
response of five patients with de novo disease causing variants in SLC35A2 
and then summarise clinical details of published cases. The paper is well 
written and represents a significant addition to current literature as no similar 
detailed review exists.  
I would recommend the following changes and corrections; 
1. In the methods section, the authors should include brief details about how 
the patients were ascertained. This will allow the reader to understand any 
effect of ascertainment bias on reported phenotypic features.  
NEED TO CHECK WITH AUTHORS RE ASCERTAINMENT AS ABOVE 
 
2. Carbamazapine should be Carbamazepine 
Thank you, this has been altered.  
 
3. For consistency the authors should include brief details of the skeletal 
anomalies including coxa valga in the main case report for patient 1 as well as 
in the supplementary information.  
Thank you, this information has been added to the case report.  
 
4. The authors state that µ7KH X-rays of the pelvis in both patients 1 and 2 
showed bilateral coxa valga with high migration index on both sides, 
suggesting this may be a specific ILQGLQJ¶ Therefore radiographs illustrating 
this from patient 1 as well should be included if possible.  
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Thank you, unfortunately these radiographs were not available for this 
revision.  
 
5. Cortical visual impairment is due to CNS dysfunction and is not strictly an 
ophthalmic abnormality. Visual defect may be a better term.  
Thank you, µRSKWKDOPLF DEQRUPDOLW\¶ has been altered to µYLVXDO GHIHFW¶ in both 
the text and table 2.  
 
6. Table 1 does not need to include a full text description of patient 
dysmorphology. Instead this should be moved to the supplementary case 
reports.  
Thank you, the description of dysmorphology has been moved to case 
reports.  
 
7. In table 1 OFC centiles should be included in the microcephaly line 
Thank you, microcephaly has been replaced by OFC centile.  
 
8. Genomic coordinates for all variants should be included in table 1.  
Thank you for this comment, but as details of the transcript and genome build 
are included we do not feel the genomic coordinates are necessary. Details of 
the transcript number have been added to the table legend.  
 
9. In table 2 in the lines for MRI, skeletal and ophthalmic abnormality it would 
be better to include a couple of words or an abbreviation summarising the 
abnormality rather than Y and N with the description being in the legend. The 
reader could then see the spectrum of abnormalities more easily.  
Thank you. The table has been altered to include abbreviations summarising 
the abnormalities found. 
  
10. µ9LVXDO GHIHFW¶ or µ9LVXDO LPSDLUPHQW¶ is preferable to µ2SKWKDOPLF 
DEQRUPDOLW\¶ because cortical visual impairment is not strictly an ophthalmic 
abnormality.  
Thank you, µRSKWKDOPLF DEQRUPDOLW\¶ has been altered to µYLVXDO GHIHFW¶ 
 
11. µ/RZ set KDLU¶ should be µORZ anterior KDLUOLQH¶  
Thank you. This has been altered in the supplementary data.  
 
12. Figure 1 legend ± µD protruding tongue QRWH¶ should be corrected.  
Thank you, this has been corrected.  
 
13. Figure 1 ± the photos do not appear to confirm mild 2-3 toe syndactyly in 
patient 3. 
Thank you, reference to this has been removed.  
 
14. Figure 1 ± patient 3. It LVQ¶W clear what µVOLJKWO\ overhanging FROXPHOOD¶ 
means ± suggest omitting this.  
Thank you, this has been omitted.  
 
15. µ1RQH of the four patients reported KHUH«¶ The authors report describes 
five patients.  
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Thank you, this has been corrected to µILYH SDWLHQWV¶  
 
16. The authors state that µFRPPRQ features include short VWDWXUH«FR[D 
YDOJD¶ None of these features appear to be particularly common so it would 
be better just to state that µ6NHOHWDO features LQFOXGHG«¶  
Thank you, this has been altered to µ)HDWXUHV LQFOXGH«¶ 
 
 
 
Yours sincerely, 
 
Dr Michael Yates MBChB MSc MRCP 
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Abstract 
 
We aim to further delineate the phenotype associated with pathogenic 
variants in the SLC35A2 gene, and review all published literature to-date. This 
gene is located on the X chromosome and encodes a UDP-galactose 
transporter. Pathogenic variants in SLC35A2 cause a congenital disorder of 
glycosylation. The condition is rare, and less than twenty patients have been 
reported to-date. The phenotype is complex and has not been fully defined.  
Here, we present a series of five patients with de novo pathogenic variants in 
SLC35A2. The SDWLHQWV¶ phenotype includes developmental and epileptic 
encephalopathy with hypsarrhythmia, facial dysmorphism, severe intellectual 
disability, skeletal abnormalities, congenital cardiac disease and cortical visual 
impairment.  
Developmental and epileptic encephalopathy with hypsarrhythmia is present 
in most patients with SLC35A2 variants, and is drug-resistant in the majority 
of cases. Adrenocorticotropic hormone therapy may achieve partial or 
complete remission of seizures, but the effect is usually temporary. Isoelectric 
focusing of transferrins may be normal after infancy, therefore a congenital 
disorder of glycosylation should still be considered as a diagnosis in the 
presence of a suggestive phenotype. We also provide evidence that cortical 
visual impairment is part of the phenotypic spectrum. 
Running title: SLC35A2: defining the phenotype 
 
Keywords: Developmental and epileptic encephalopathy, Congenital 
disorders of Glycosylation, Intellectual Disability, SLC35A2 
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Introduction 
 
Over 100 glycosylation-related human genetic disorders have been reported 
in the literature. These result from disruption of the normal N-glycosylation 
pathway which involves adding complex sugar chains (glycans) to proteins1. 
Congenital disorders of glycosylation (CDG) can result in a complex 
phenotype, including intellectual disability and seizures2-3. Variants in the 
SLC35A2 gene (MIM #300896), on the X chromosome, coding for the only 
known transporter of UDP-galactose to the Golgi apparatus, have been found 
to result in a congenital disorder of glycosylation4. To the DXWKRUV¶ knowledge, 
less than twenty patients with variants in this gene have been reported in 
detail to-date3-10. The associated phenotype includes developmental and 
epileptic encephalopathy (EE), severe intellectual disability (ID), hypotonia, 
dysmorphic features, and shortening of the distal limbs.  
 
Here, we present five new patients with de novo pathogenic variants in 
SLC35A2, who have EE with hypsarrhythmia, severe ID, skeletal 
abnormalities and cortical visual impairment. We further define the phenotypic 
spectrum, in particular the epilepsy phenotype. With increasing use of next 
generation sequencing in patients with epilepsy, it is likely that more patients 
will be identified with this phenotype and hence, it is important to better 
understand the disease course and potential treatment options in this group of 
disorders. 
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Patient Reports 
 
Our cohort consists of five female patients born to non-consanguineous White 
European parents (Fig.1). All patients had normal chromosomal microarray 
analysis (Patient 1 was found to have a paternally inherited 320 kb deletion at 
6q26, classified as likely benign). All were found to have heterozygous de 
novo variants in SLC35A2 with no additional variants. Patient 4 was also 
found to have a skewed X chromosome inactivation profile (100:0). Three 
patients had normal isoelectric focusing of transferrins, performed between 
the ages of 2 and 8 years. In addition to the reports here, Table 1 provides 
further clinical information. Further details are included in the supplementary 
material.   
 
Patient 1  
This 3-year old patient developed infantile spasms at 6-weeks of age. EEG 
(electroencephalogram) demonstrated hypsarrhythmia. Magnetic Resonance 
Imaging (MRI) of the brain at 7-months of age demonstrated asymmetry of the 
lateral ventricles and a thin corpus callosum (Supp Fig. 1). She had a partial 
response to Vigabatrin and Prednisolone. Her seizures subsequently evolved 
to myoclonic and tonic seizures in addition to ongoing spasms with clusters. 
These were resistant to several different treatment regimens including 
combinations of Vigabatrin, steroids, Sodium Valproate, Levetiracetam, and 
Topiramate. Seizure control improved on classical ketogenic diet therapy at 
12-months of age, together with cessation of all anti-epileptic medications. A 
course of ACTH (adrenocorticotropic hormone) therapy resulted in a definite, 
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but short-lived, improvement in seizure control. Response to a second course 
of ACTH was less effective. 
 
She had significant developmental impairment. Tetralogy of Fallot was noted 
on antenatal ultrasound (USS), which subsequently required surgery. On 
assessment at the age of 3-years, she was noted to be dysmorphic and had 
right lower limb shortening. Radiological review of a skeletal survey 
demonstrated thoracic scoliosis, bilateral coxa valga and generalised 
osteopenia. There were unusual defects involving the right proximal and distal 
tibia, with the defect in the proximal tibia being larger. Overall, the right tibia 
was shorter than the left. Possible similar early changes were seen in the left 
distal tibia (Fig. 2). The significance of these radiological findings remains 
uncertain. 
She also has severe cortical visual impairment, with no response to formal 
visual acuity assessment but some brief fixation. Electroretinogram (ERG) 
confirmed no evidence of diffuse retinal dysfunction. 
 
Patient 2  
This 8-year old patient developed infantile spasms at the age of 5-months. 
EEG showed hypsarrhythmia and an MRI brain scan was normal. Initial 
treatment was with Prednisolone and subsequently Vigabatrin with partial 
response. Over the course of the next few years she developed drop attacks, 
tonic spasms, and changes in visual attention associated with an unusual cry. 
Her seizures were resistant to ketogenic diet, as well as combinations of 
Lamotrigine, Zonisamide, Nitrazepam, Rufinamide, and Topiramate. Repeat 
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EEG at the age of 4-years and 3-months showed hypsarrythmia. Repeat MRI 
brain imaging at the ages of 18 and 31 months showed significantly delayed 
cerebral white matter myelination. This normalised by age 4-years, with some 
residual hyperintensity posterior to the trigones of the lateral ventricles. The 
hippocampi appeared small and malrotated (Supp Fig. 2).  
 
She had severe developmental delay. On assessment at the age of 8-years 
she had severe ID and was able to walk a few steps with support. She was 
dysmorphic. A pelvis x-ray showed bilateral coxa valga with partial hip 
subluxation (Fig.2).  
 
Patient 3  
This 8-year old patient developed infantile spasms at 6-months of age. EEG 
demonstrated hypsarrhythmia. Her seizures responded to Vigabatrin in 
combination with ACTH. She was then treated with Valproate monotherapy. 
From the age of 3 ½ years, medication was withdrawn and she remained 
seizure-free. Neonatal nystagmus was noted, which ceased as seizure control 
improved. She had myopia, astigmatism, intermittent exotropia of the right eye 
and amblyopia ex anopsia. ERG performed at 14-months of age was normal. 
MRI brain and echocardiogram at the age of 8-months was normal.  
 
On assessment at the age of 3-years and 4-months, she had severe 
hypotonia and severe global developmental delay. She was dysmorphic. At 
the age of 8-years, she has severe ID with no spoken language. She can walk 
with support if helped to a standing position. 
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Patient 4 
This 3-year old patient developed infantile spasms at 6-weeks of age and 
EEG demonstrated hypsarrhythmia. Her spasms were partially controlled with 
a combination of Vigabatrin, steroids and ACTH therapy. She was treated 
unsuccessfully with Phenobarbital, Valproate, Levetiracetam and Topiramate. 
Her spasms ceased with a combination of Vigabatrin, Nitrazepam and 
ketogenic diet at 2-years and 3-months of age. MRI brain scan at two months 
was normal. A second MRI brain at 2 ½ years of age demonstrated thinning of 
the corpus callosum with delayed myelination and slight enlargement of the 
lateral ventricles. On assessment at 3-years and 4-months of age, she had 
global hypotonia. She could sit and stand with help. She had no spoken 
language. She had severe ID. She was dysmorphic. There were no 
ophthalmic abnormalities.  
 
Patient 5 
This 10-month old patient developed eye rolling and chewing episodes at the 
age of four months, as well as unilateral myoclonic jerks. There was one 
episode of opisthotonus. Focal epileptic activity was noted on EEG at the age 
of five months, however this did not correlate with clinical episodes. 
Carbamazepine and then Levetiracetam monotherapy was trialled, but did not 
have a significant effect and was discontinued. MRI brain was normal.   
 
On assessment at the age of 10-months, she had moderate to severe 
developmental delay. She had hypotonia, and was dysmorphic. There were 
no ophthalmic abnormalities.  
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Methods 
 
Patients 1,2 and 4 were ascertained through routine referral to their local 
Clinical Genetics service, with a referral indication of drug-resistant 
developmental and epileptic encephalopathy. The cohort was formed through 
personal communication (Patient 2), interrogation of the DECIPHER 
database11 (Patient 3) and through the GeneMatcher website12 (Patients 4 
and 5). Genomic DNA was extracted from peripheral blood leukocytes from 
patients using standard procedures. All patients underwent chromosomal 
microarray-analysis.  
 
For patients 1 & 2, sequencing of 72 genes associated with early infantile 
epileptic encephalopathy was carried out using targeted whole exome 
sequencing (WES) (Agilent SureSelect and MiSeq). Trio-based whole 
genome sequencing (WGS) was carried out for patient 3 using the Illumina 
HiSeqX system (Illumina). For patient 4, sequencing of a 93 gene panel for 
monogenic epileptic disorders was performed on a NextSeq500 (Illumina). 
WES was performed for patient 5 using NovaSeq 6000 Agilent SureSelect All 
Human Exon v6. All data was analysed against GRCh37. All variants reported 
are according to the NM_005660.2 transcript. Variants were verified by 
Sanger sequencing using standard protocols. Methods are described in 
further detail in the supplementary material. 
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Discussion  
 
We present here a series of five patients with de novo pathogenic variants in 
SLC35A2 and phenotypic features including epilepsy with hypsarrhythmia, 
severe ID, non-specific dysmorphism, visual and skeletal abnormalities.  
 
Comparison of our cohort with those previously reported3-10 allows us to 
define the phenotype associated with SLC35A2, particularly in relation to 
epilepsy, which affects 16/18 (89%) patients (Table 2). Seizures start in early 
infancy, with 8/11 (73%) of those reported developing before the age of 3-
months and all before 6-months. The presentation was with infantile spasms 
in 8/10 (80%). Two patients presented with tonic seizures and partial motor 
seizures respectively. The phenotype was reported, in six patients, to 
progress to a combination of tonic seizures plus spasms. Two patients were 
also reported to have myoclonic seizures. Hypsarrhythmia is common (13/16; 
81%). Given that all affected patients have developmental delay, this means 
most meet the criteria for West syndrome (triad of infantile spasms, 
hypsarrhythmia and developmental delay). Epilepsy in this group is usually 
resistant to treatment with 64% of patients having ongoing seizures.  
 
There does not appear to be a definite pattern to response in treatment, but 
our experience suggests that partial and/or temporary seizure control may be 
achieved with either Vigabatrin +/- steroids, the ketogenic diet or ACTH. Four 
previously reported patients have had a temporary response to ACTH, with a 
further patient achieving seizure control with this therapy3,6-7. As these are 
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standard treatments for infantile spasms, further work is needed to determine 
optimal epilepsy medication in this group of patients.  
 
All patients reported have severe ID. None of the five patients reported here 
had developed spoken language. Non-specific dysmorphic features are 
present in 16/17 (94%). Hypotonia (12/18; 67%) and microcephaly (6/13; 
46%) are common. Fifteen out of 18 (83%) patients have abnormalities on 
brain MRI. The most common findings are thinning of the corpus callosum 
(8/18; 44%), cerebral and/or cerebellar atrophy (8/18; 44%) and delayed 
myelination (6/18; 33%). One patient in our cohort had a normal MRI brain 
scan at the age of 8-months. Interestingly, however, two previously reported 
patients3 initially had normal MRI-brain scans in infancy. Subsequent imaging 
at the ages of 4 and 8 years respectively was abnormal. Therefore, it is 
possible that SLC35A2-associated brain abnormalities develop over time, and 
this may well prove to be the case in our patient with an early normal MRI 
brain scan. 
 
Visual defects are present in 11/16 (69%) individuals. Of note, one other 
patient has been previously reported with cortical visual impairment5, although 
the patient of Dörre et al.6 had severe visual impairment of unspecified cause. 
Therefore, our report provides further evidence that this specific visual 
abnormality is part of the phenotypic spectrum associated with SLC35A2 
pathogenic variants. However, it is also possible that in view of EE, visual 
impairment may be a part of the phenotype rather than a specific issue. 
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Skeletal abnormalities are found in 9/14 (64%) patients. Features include 
short stature, non-specific limb shortening, scoliosis and bilateral coxa valga. 
The X-rays of the pelvis in both patients 1 and 2 showed bilateral coxa valga 
with high migration index on both sides, suggesting this may be a specific 
finding. Further imaging of patients with SLC35A2 is required to ascertain the 
skeletal findings in this group. 
Our cohort includes one patient with Tetralogy of Fallot. This has not been 
reported in association with SLC35A2 and may represent a novel feature. 
However, this cardiac abnormality can occur in isolation and further reports 
are required to determine if congenital cardiac disease is part of the SLC35A2 
phenotypic spectrum.  
 
Transferrin isoelectric focusing was normal for those tested in our cohort at 
ages 3-years 4-months and 2-years 6-months respectively (Patients 3 & 4). 
The majority of reported patients, including our cohort, had normal transferrin 
profiles after the age of 2-years (Table 2). Ng et al.4 demonstrated 
galactosylation-deficient transferrin profiles in their patient series between the 
ages of 5-7 months, with normalisation after the age of 3 years. Therefore, 
there is likely to be an age-related time period for transferrin testing in relation 
to SLC35A2-related CDG, emphasising the importance of early diagnosis. Ng 
et al.4 hypothesised this is related to selection against hepatocytes with 
abnormal SLC35A2 during early development; however, this has not been 
conclusively demonstrated. Our data suggest that isoelectric focusing of 
transferrins is a useful diagnostic test in females presenting with early onset 
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infantile spasms. This analysis should be performed before three years of age 
if feasible.  
 
SLC35A2 is located on the X chromosome; all of our patients are females, in 
keeping with majority of patients reported thus far. Ng et al.4 reported two 
male patients who were mosaic for SLC35A2 pathogenic variants. It is likely 
that the presence of a functional allele is required for survival. There have 
been two reports of maternal inheritance in the literature8,10; otherwise all the 
pathogenic variants reported are de novo. Our cohort includes three novel 
missense variants and one novel nonsense variant. Overall, including our 
cohort, missense and truncating variants have been reported in the literature 
at approximately equal frequency.  
 
In summary, we present a series of five patients with pathogenic SLC35A2 
variants and review the features of patients previously reported, with particular 
focus on the drug-resistant epilepsy phenotype and MRI brain findings. This 
allows us to further define the phenotype of this rare disorder. Early onset 
epilepsy presenting with infantile spasms and hypsarrhythmia predominates, 
in association with severe developmental delay and ID. Interestingly, severe 
early-onset epilepsy is unusual in CDGs in general. This appears to be a 
feature unique to SLC35A2-related CDG.  
 
Additional common features include non-specific dysmorphism, microcephaly, 
hypotonia and MRI-brain abnormalities (e.g. thinning of the corpus callosum 
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and cerebral atrophy). Visual and skeletal defects may be present, but further 
data is required to determine how specific these are in relation to SLC35A2.   
In this respect, we provide evidence that cortical visual impairment is part of 
the phenotypic spectrum. Additionally, congenital cardiac disease may be part 
of the extended phenotype. Further patient series of this nature are required 
to understand the natural history and course of the seizure phenotype in 
patients with rare genotypes, such as those with pathogenic variants in 
SLC35A2.  
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Figure legends 
 
 
 
 
Figure 1. Patients 1 (a,d,g,h), 2 (b,e) and 3 (c,f,i,j) at ages 11-months, 8-years and 11-months, and two-
years respectively. Patient 1: dysmorphic features include brachycephaly, hypertelorism, and low-set 
ears. Note 2-3 toe syndactyly (R foot) and proximally placed 2nd toe (L foot). Patient 2: dysmorphic 
features include high-set eyebrows, long, narrow palpebral fissures, mid-face hypoplasia with 
depressed nasal bridge, open mouth with full, tented upper lip and a protruding tongue. Patient 3: 
dysmorphic features include elongated palpebral fissures, large blue irises; eversion of the lower lids; 
long and prominent eyelashes; broad eyebrows; short nose and hypoplastic alae nasi; short, grooved 
philtrum; tented upper lip and posteriorly-rotated ears. Also note tapering fingers and broad great toes.  
Figure 2. Patient 1 (a-b): radiographs at 11-months of age demonstrating non-specific defects 
involving the right proximal and distal tibia, with the proximal tibia being larger. Patient 2 (c): 
radiograph of pelvis demonstrates bilateral coxa valga with partial hip subluxation.  
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 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Gender F F F F F 
Age at evaluation 
(yr;mo) 
3 8;11 8;0 3;4 0;10 
SLC35A2 variant 
(predicted protein 
change) 
c.889A>G 
(p.Lys297Glu) 
c.327T>G 
(p.Tyr106*) 
c.195C>A 
(p.Phe65Leu) 
c.515T>C (p.Leu172Pro) c.923C>T (p.Ser308Phe) 
ACMG pathogenicity 
criteria 
PS2, PM2 and 
PP3 (Likely 
pathogenic)  
PVS1,PS2 
(Pathogenic) 
 PS2, PM2, PP3, 
PP4 (Likely 
pathogenic) 
PS2, PM2 and PP3 (Likely 
pathogenic)   
PS2, PM2, PP2, PP3 
(Likely pathogenic) 
Family history Cousin X-linked 
agammaglobulina
emia 
Brother single 
febrile seizure 
Unremarkable Unremarkable Unremarkable 
Antenatal findings Tetralogy of Fallot  Nil Nil Nuchal thickening Nil 
Gestational age at 
birth (weeks) 
40 34 43 40 38 
Birth weight 50th centile 25-50th centile 25th centile 40th centile 75th-91st centile 
Admission to NICU Yes ± Tetralogy of 
Fallot 
Yes - Weight 
loss, jaundice, 
skin ulcers 
No No Yes - CPAP 
Dev. delay Yes Yes Yes Yes Yes 
ID n/a Severe Severe Severe n/a 
Age of seizure onset 6 weeks 5 months 6 months 6 weeks Possible at age 4 months 
Initial seizure type Infantile spasms Infantile spasms Infantile spasms Infantile spasms Eye rolling/chewing 
episodes 
Evolving seizure 
phenotype 
Myoclonic & tonic 
seizures; and 
ongoing spasms 
with clusters 
Drop attacks, 
tonic spasms, 
change in visual 
attention 
n/a n/a n/a 
EEG Hypsarrhythmia Hypsarrhythmia Hypsarrhythmia Hypsarrhythmia Focalised epileptic activity 
AED response Partial  Pharmacoresista
nt 
Seizure free, off 
medication 
Seizure free on  Vigabatrin, 
Nitrazepam and ketogenic 
diet 
AED stopped with no 
clinical change 
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 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Dysmorphic Yes Yes Yes Yes Yes 
Hypotonia No No Yes Yes Yes 
Head circumference 
centile (age) 
9th (11mo) <<0.4th (9yr) 98th-99.6th (birth) 40th (3y 4mo) 50th (10mo) 
Visual defect Severe cortical 
visual impairment 
No Myopia, 
astigmatism, 
intermittent 
exotropia of the 
right eye and 
amblyopia ex 
anopsia 
No Strabismus 
Skeletal abnormality Thoracic scoliosis, 
bilateral coxa 
valga and 
generalised 
osteopenia. 
Unusual defects 
involving the right 
proximal and 
distal tibia, with 
right tibia shorter 
than the left. 
Possible similar 
early changes in 
the left distal tibia 
Bilateral coxa 
valga with partial 
hip subluxation 
Joint 
hypermobility, 
genu valga, 
asymmetric 
chest deformity 
Camptodactyly of the 2nd 
right finger 
n/a 
MRI abnormality 
(age) 
Asymmetry of the 
lateral ventricles 
and a thin corpus 
callosum (7 mo) 
Normal (5mo). 
Delayed cerebral 
white matter 
myelination (18 & 
31mo). 
Normalised with 
some residual 
hyperintensity 
posterior to the 
trigones of the 
lateral ventricles 
(4yr). Hippocampi 
small and 
malrotated 
No Normal (2mo). Thinning of 
the corpus callosum with 
delayed myelination and 
slight enlargement of the 
lateral ventricles (2.5yr). 
No 
Isf Tf (age -yr;mo) nd normal (8;11) normal (3;4) normal (2;6) nd 
Table 1. Features of patients in this cohort. Isf Tf isoelectric focusing of transferrins;  n/a not applicable; nd not done; AED 
antiepileptic medication. All variants are according to the NM_005660.2 transcript. 
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Patient 1 Patient 
2 
Patient 
3 
Patient 4 Patient 5 Ng et al. 
(Patient 1) 
Ng et 
al. 
(Patie
nt 2) 
Ng et 
al. 
(Patient 
3) 
Kodera et 
al. (Patient 
1) 
Kodera et 
al. (Patient 
2) 
Kodera 
et al. 
(Patient 
3) 
Bosch et 
al.  
Kimizu et 
al. 
Dorre et 
al.  
Lopes et 
al. 
EuroEPIN
OMICS et 
al (Patient 
1) 
EuroEPIN
OMICS et 
al (Patient 
2) 
Evers et 
al. 
Total 
(report
ed) 
Gender F F F F F M F M F F F F F F M F F F - 
Age 
(yr;mo) 
3 8;11 8;0 3;4 0;10 3 3 6 8;10 12;8 10;5 23 2 5 8 3 13 2 - 
Inher. de novo de novo de novo de novo de novo de novo de 
novo 
de novo de novo de novo de novo de novo de novo de novo mat de novo de novo mat - 
SLC35A2 
variant  
c.889A>
G 
c.327T>
G 
c.195C
>A 
c.515T>
C 
c.923C>T c.15_91+48
delinsA 
c.3G
>A 
c.991G
>A 
c.433_434d
el 
c.972del c.638C>
T 
c.800A>
G 
c.950delG c.797G>
T 
c.772G>
A 
c.683C>A c.502C>T c.831C>
G 
- 
Predicted 
protein 
change 
p.Lys29
7Glu 
p.Tyr10
6* 
p.Phe65
Leu 
p.Leu17
2Pro 
p.Ser308Ph
e 
p.Gly8Serfs
*9 
p.Met
1? 
p.Val33
1Ile 
p.Tyr145Pr
ofs*76 
p.Phe324Le
ufs*25 
p.Ser21
3Phe 
p.Tyr26
7Cys 
p.Gly317Al
afs*32 
p.Gly26
6Val 
p.Val25
8Met 
p.Ser228* p.Gln168* p.Asn27
7Lys 
- 
Isf Tf (age 
-yr;mo) 
nd nml 
(8;11) 
nml 
(3;4) 
nml 
(2;6) 
nd abn (0;5), 
nml (3;2) 
abn 
(0;7), 
nml 
(2;9) 
abn 
(0;5-7), 
nml 
(5;0) 
nml (8;10) nml (12;8) nml 
(10;5) 
nd mass 
spectrometr
y nml 
(1;0),(2;6) 
abn 
(0;1), 
(5;0) 
nml 
(8;0) 
nd nd abn (2;0) - 
Dev. delay S S S S M-S Y Y Y S S S Y S S S nd S S 17 of 
17 
(100%
) 
ID n/a S S S n/a n/a n/a nd S S S S n/a nd S Y S nd 10 of 
10 
(100%
) 
Seizures Y Y Y Y N Y Y N Y Y Y Y Y Y Y Y Y Y 16 of 
18 
(89%) 
Age 
seizure 
onset 
6wk 5mo 6mo 6wk n/a nd nd nd 6 days 1mo 3mo nd 2mo 3mo nd 3mo 4.5mo nd - 
Initial 
seizure 
type 
Infantile 
spasms 
Infantile 
spasms 
Infantil
e 
spasms 
Infantile 
spasms 
n/a nd nd nd Tonic  Infantile 
spasms 
Infantile 
spasms 
nd Partial 
motor 
seizures 
upper limbs 
nd nd Infantile 
spasms 
Infantile 
spasms 
nd - 
Evolving 
seizure 
phenotype 
Myoclo
nic and 
tonic + 
ongoing 
spasms 
with 
clusters 
Drop 
attacks 
+ tonic 
spasms 
n/a n/a n/a nd nd nd Infantile 
spasms + 
tonic 
seizures 
Tonic 
seizures, 
spasms, 
focal 
seizure 
Tonic 
seizure, 
spasms 
nd Spasms nd nd Spasms + 
tonic 
seizures 
Myoclonic, 
tonic-
clonic, 
tonic 
nd - 
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Table 2. Summary of patients with pathogenic SLC35A2 variants previously reported, including this study cohort. 
Brain abnormalities: TC: thin corpus callosum, AV: abnormal ventricles, DM: delayed myelination, CA: cerebral/cerebellar atrophy,  
Ophthalmic abnormalities: CV: cortical visual impairment, RA: refractive error, EM: abnormal eye movements, RA: retinal abnormality  
Skeletal abnormalities: SC: scoliosis, CV: coxa valga, GV: genu valga, SE: shortened extremities, HD: hip dislocation, JH: joint hypermobility  
Abbreviations: Inher. - inheritance, yr - year, mo - months, dn - de novo, mat - maternal, Y - yes, N - no, ACMG-AMP  - American College of Medical Genetics and Genomics ± Association for Molecular Pathology, 
Isf Tf - Isoelectric focusing of transferrins S - severe, M-S ± moderate to severe, ctrl - controlled, nd - not documented, Dev - developmental, ID - intellectual disability, nml - normal, abn - abnormality, ophthal - 
ophthalmic 
 
 
Patient 1 Patient 
2 
Patient 
3 
Patient 4 Patient 5 Ng et al. 
(Patient 1) 
Ng et 
al. 
(Patie
nt 2) 
Ng et 
al. 
(Patient 
3) 
Kodera et 
al. (Patient 
1) 
Kodera et 
al. (Patient 
2) 
Kodera 
et al. 
(Patient 
3) 
Bosch et 
al.  
Kimizu et 
al. 
Dorre et 
al.  
Lopes et 
al. 
EuroEPIN
OMICS et 
al (Patient 
1) 
EuroEPIN
OMICS et 
al (Patient 
2) 
Evers et 
al. 
Total 
(report
ed) 
Seizures 
ctrl 
N N Y Y n/a nd nd nd N N N nd Y Y nd N N nd 4 of 
11 
(36%) 
Hypsarrhy
thmia 
Y Y Y Y N Y Y N Y Y Y nd Y Y N Y Y nd 13 of 
16 
(81%) 
Dysmorph
ism 
Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y nd 16 of 
17 
(94%) 
Hypotonia N N Y Y Y Y Y Y Y N Y Y Y Y N Y N N 12 of 
18 
(67%) 
Microceph
aly 
N Y N N N N Y Y nd nd nd Y N Y Y nd nd N 6 of 
13 
(46%) 
MRI abn. TC, AV DM  N DM, TC N Small 
cerebellum 
DM, 
TC 
CA TC, DM, 
CA 
AV CA, TC DM TC,  CA, 
AV 
CA, TC CA, TC, 
perivent
ricular 
heteroto
pia 
N DM, CA CA 15 of 
18 
(83%) 
Visual 
defect 
CV N RA N EM EM RA EM N RA N CV N µVHYHUH 
visual 
impairm
HQW¶ 
nd nd EM Cataract 11 of 
16 
(69%) 
Skeletal 
abn. 
SC CV JH, GV N N N SE SE N N HD SC nd JH nd nd SC nd 9 of 
14 
(64%) 
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